Lack Of Interchangeability No Barrier For Amjevita, Says Amgen Executive

Company Expects Product To Receive Designation Some Time After January Launch

 
• By Chloe Kent
  
Amgen company signboard
Amjevita is expected to be the first biosimilar adalimumab to launch in the US market • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products